Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380939 · ClinicalTrials.gov registry record · Phase 4
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
A Phase 4 study of Coronary Arteriosclerosis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT00380939 is a Phase 4 study of Coronary Arteriosclerosis that has completed, run by Pfizer. The registered enrollment target is 600 participants, below the 663-participant average among 11 other Coronary Arteriosclerosis trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00380939, a Phase 4 study of Coronary Arteriosclerosis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity.
Conditions Studied
Interventions
- DRUG Atorvastatin
- DRUG Pravastatin
Study Locations (20)
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - San Diego
Michigan
- Pfizer Investigational Site - Kalamazoo
- Pfizer Investigational Site - Royal Oak
- Pfizer Investigational Site - Saint Clair
New York
- Pfizer Investigational Site - Albany
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - Williamsville
Florida
- Pfizer Investigational Site - BLUE Island
- Pfizer Investigational Site - Gainesville
Arkansas
- Pfizer Investigational Site - Little Rock
Colorado
- Pfizer Investigational Site - Denver
Georgia
- Pfizer Investigational Site - Atlanta
Illinois
- Pfizer Investigational Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 1999-04 |
| Est. Completion | 2000-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380939
The ClinicalTrials.gov registry entry for NCT00380939 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 663-participant average among 11 other Coronary Arteriosclerosis trials with a reported enrollment target (10% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Arteriosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Atorvastatin is the first listed.
NCT00380939 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT00380939 about?
NCT00380939 is a clinical study titled "This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.". This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity.
What is the current status of trial NCT00380939?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 1999-04. Estimated completion is 2000-12.
What conditions does trial NCT00380939 study?
This clinical trial studies the following conditions: Coronary Arteriosclerosis.
What interventions are being tested in trial NCT00380939?
The interventions under investigation include: Atorvastatin (DRUG), Pravastatin (DRUG).
Who is sponsoring clinical trial NCT00380939?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00380939 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Arteriosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique
ACTIVE NOT RECRUITING · NA
-
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
COMPLETED · Phase 2
-
Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)
COMPLETED · NA
-
Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients
COMPLETED · NA
-
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
COMPLETED · NA
-
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.